Skip to content
Review

Bioenergetic impairment-induced Tau acetylation: Converging pathways in Alzheimer's disease.

2026 · International review of neurobiology · Vol 187, pp. 17-38 · 0 citations
Medicine

TL;DR

Understanding the metabolic pathways that drive tau acetylation may offer new therapeutic targets aimed at restoring neuronal energy balance, re-establishing acetylation homeostasis, and potentially slowing the progression of AD.

View source

Similar papers

Review 2026

Metabolic therapeutic targets in Alzheimer's disease.

This chapter examines key metabolic pathways implicated in AD, including cerebral glucose hypometabolism, brain insulin resistance, impaired glycolysis, mitochondrial oxidative phosphorylation deficits, oxidative stress, and altered mitochondrial dynamics, and discusses therapeutic strategies aimed at restoring metabol...

Ignatius Raymond Peter L, Debojyoti Chatterjee, A. F. Chrishone et al. · 0 citations
Review 2026

The Tau-mitochondria connection and its impact on cellular energy metabolism in Alzheimer's disease.

This chapter looks at the nature of the tau-mitochondrial interface, and proposes a paradigm of tau-induced energy failure in AD, and discusses novel therapeutic approaches that target both tau and mitochondrial abnormalities, namely antisense oligonucleotides (ASO), mitochondria targeted compounds and mitophagy modifi...

Abhay Kumar Singh, Supraja M. R., Amal P. S. et al. · 0 citations
Review Open access Aug 2026

Insulin resistance as a driver of neuroinflammation and oxidative stress in Alzheimer's disease: Mechanistic links and therapeutic approaches.

This narrative review examines the mechanistic interplay among insulin resistance, oxidative stress, and neuroinflammation in AD, with particular emphasis on the shared cellular pathways that underlie disease progression and summarizes emerging therapeutic strategies targeting insulin signaling.

Parinaz Hajeforoosh, A. H. Moghaddam, S. K. Jelodar · 2 citations
Review 2026

Energetic crisis, mitochondrial vulnerability and disruption of lactate shuttle in Alzheimer's disease.

Cerebral bioenergetic metabolic failure as a central driver of cognitive decline, arising from irreversible reactive gliosis and neuroblastosis mechanisms is emphasised and various therapeutic options are highlighted, including restoration of ANLS to mitigate the pathogenesis and memory loss in AD.

Gowsika Baskar, Mahesh Kandasamy · 2 citations
Review 2026

Brain lipid dysregulation as a driver of energy metabolism failure in Alzheimer's disease.

This chapter addresses the gap and consolidates existing information connecting lipid modifications to metabolic dysfunction in AD, emphasizing molecular pathways and prospective treatment strategies aimed at lipid metabolism to re-establish bioenergetic equilibrium.

Nitin Yadav, Jyotirmoy Banerjee, Manisha Tiwari et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.